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Macrophages are now recognized to be important cellular targets in HIV infec-
tion . These cells can be infected with HIV in vitro (1-7) and express HIV antigens
and nucleic acid in vivo (8-13) . Macrophage-tropic forms of HIV can be isolated
from brain, lung, and blood (4, 7, 14), and these isolates replicate for months in
monocyte-derived macrophages in vitro (4). Unlike CD4 T cells, macrophages are
not rapidly killed byHIVand may serve as a persistent viral reservoir. HIVinfected
macrophages may also have a critical role in the immunological disturbances and
encephalopathy ofHIV infection (15-17) . Furthermore, cultured macrophages con-
tain reduced levels of the kinases required to activate dideoxynucleosides such as
AZT, and may not be protected by these agents as efficiently as T cells (18) . Thus,
additional therapeutic strategies for HIV infection may be needed in order to ad-
dress the special biology of HIV infection in macrophages .
Numerous studies have demonstrated the effect of various stimuli upon macro-
phage functions (19, 20) . Endotoxin, in the form ofbacterial lipopolysaccharide (LPS),
profoundly affects many macrophage functions (21) . Also, endogenous cytokines such
as interferons may physiologically "activate" macrophages . It has been proposed that
the depletion of IFN-,y-producing T cells in AIDS leads to a defect in macrophage
activation (22), and consequently IFN--y is now entering clinical trials in AIDS pa-
tients . IFN-a and IFN-(3 are already being tested in patients . However, the possi-
bility that these interferons have antiviral effects against HIV in macrophages has
not been examined . In this study, we demonstrate that treatment with IFN-a, IFN-
0, IFN-y, or LPS prevents the establishment of productive HIV infection in cul-
tured macrophages .
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Materials and Methods
Macrophage Culture.
￿
PBMC were isolated from the blood of healthy volunteers by cen-
trifugation over Ficoll-Hypaque. Monocytes were initially isolated by adherence to fibronectin
(23) . These cells were 70-90% nonspecific esterase (NSE)'-positive (Kit 90-Al ; Sigma Chem-
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67019, and EY03093 and by the Veterans Administration . Address correspondence to Dr . Richard S .
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' Abbreviations used in this paper : GM-CSF, granulocyte/macrophage colony-stimulating factor; M-CSF,
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ical Co., St. Louis, MO) and were further purified by adherence to plastic. Initially, 4 x
105 fibronectin-adherent cells were cultured in 1 ml of RPMI 1640 (Whittaker M. A. Bi-
oproducts, Inc., Walkersville, MD or Irvine Scientific, SantaAna, CA) containing 10% heat-
inactivated autologous or AB human serum and 50 ug/ml gentamicin in the 1-cm' wells of
48-well plates. All culture materials were endotoxin-free in two assays (the Limulus lysate assay
and a sensitive monocyte procoagulant activity assay) as previously described (22). Fibronectin-
adherent cells, enriched in monocytes, were cultured at 37°C in 5% CO2/957o air for 5-9 d
to allow them to mature into fully adherent cells (4). An additional purification step occurred
when the monolayers were washed four times at the time of infection (see below). The final
adherent cells (N2 x 105/well) were 100% NSE` and are referred to as "monocyte-derived
macrophages" (MDM).
HIV Infection.
￿
The HTLVIIIBa-L,ss macrophage-tropic isolate of HIV-1 was the gift of
Drs. S. Gartner and M. Popovic, National Cancer Institute, Bethesda, MD (4). The third
passage of this virus in MDM under endotoxin-free conditions in our laboratory was used
to make a virus pool which was aliquoted and stored at -70°C. This pool had an infectivity
titer by terminal dilution assay in MDM (as determined by p24 core antigen production)
of 106 50% tissue-culture infectious doses (TCID5o)/ml. This isolate fails to replicate in T
cell lines (CEM and MT2) that support many T lymphotropic strains of HIV1.
MDM were infected with HIV by replacing their medium with 0.2 ml per well of HIV
in medium containing 10% FCS (HyClone Laboratories, Inc., Logan, UT) instead ofhuman
serum. The multiplicity of infection (MOI) ranged between 0.1 and 1 in different experi-
ments as indicated. After at least 2 h of incubation to permit viral adsorption, unadsorbed
virus and residual nonadherent cells were removed by washing each well four times with 1
ml medium. Wells were refed 1 ml medium containing FCS and the indicated treatment,
and incubated for the times shown.
Interferons, Cytokines, and LPS .
￿
Additions to culture medium were made before infection
with HIV, during infection, or afterinfection, as indicated. rIFN-cx (also known as IFN-a2a,
IFN-a2, or Roferon) (2 x 108 U/mg) was obtained from Hoffmann-La Roche, Nutley, NJ.
rIFN-a (1 .8 x 108 U/mg) was the gift of Dr. C. Budd Colby, Triton Biosciences, Inc.,
Alameda, CA. rIFN-y (1.6 x 10' U/mg) was purchased from Amgen, Thousand Oaks, CA.
rIL-1/3 and IL-4 were obtained from Genzyme Corp., Boston, MA. rIL-2 (7.3 x 105 U/mg)
was obtained from New England Nuclear, Boston, MA. Recombinant macrophage colony-
stimulating factor (24) (M-CSF) was the gift of Dr. P. Ralph, Cetus Corp., Emeryville, CA.
Recombinant granulocyte/macrophage CSF (GM-CSF) (6.7 x 106 U/mg), M-CSF (25)
(8 x 105 U/mg), and IL-6 (5 x 106 U/mg) were gifts from Dr. Steven C. Clark, Genetics
Institute, Cambridge, MA. (GM-CSF was also obtained from Genzyme Corp. and used in
preliminary experiments). rTNRcx (5.02 x 10' U/mg) and lymphotoxin (TNF-0) (1 .28 x 108
U/mg) were gifts from Dr. H . Michael Shepard, Genentech, Inc., South San Francisco, CA.
Phenol-extracted LPS from Escherichia coli 0111 :B4 was from Calbiochem-Behring Corp., La
Jolla, CA.
Crude "macrophage-activating factor" was prepared from PBMC by stimulation with Con
A-Sepharose (26) . After 48 h, the supernatant medium was centrifuged and stored at 4°C
for no more than a week. Control supernatant was prepared in the same manner except that
Con A-Sepharose was omitted.
Viral Production and Cytopathology Assays.
￿
Cells were incubated for the times indicated and
0.05-0.1-ml aliquots were removed without refeeding and stored at -20°C for later assay
of p24 core antigen by ELISA (Abbott Laboratories, N. Chicago, IL). Additional aliquots
were stored at - 70°C and subsequently assayed for infectiousHIV by terminal dilution assay,
as described above. Wells were also serially observed by phase-contrast microscopy and scored
for the presence of multinucleated giant cells (->4 nuclei per cell).
Electron Microscopy.
￿
Macrophagecultures in Costar (Cambridge, MA) six-well plates were
fixed for 24 h in 2.5% glutaraldehyde buffered to pH 7 .4 with 0.1 M phosphate, washed for
1 h in phosphate buffer, and fixed for 30 min with 2 % osmium tetroxide (buffered as for
the glutaraldehyde). The fixedwells were then dehydratedthrough a graded series of ethanol
to 90% and then passed through a graded series of hydroxypropyl methacrylate from 90%
in water to 100%. Next, wells were infiltrated with sequential mixtures of hydroxypropylmethacrylate and Epon 812, starting at three parts to one part respectively and terminating
in pure Epon 812 as previously described (27). Embedding was accomplished by quickly in-
verting and setting a Beem capsule filled with Epon 812 over areas of the culture that con-
tained multinucleated giant cells or normal appearing areas. After polymerization for 48 h
at 60°C, the wells were frozen at -70 °C and the Beem capsules were snapped to remove
the cells from the plastic dishes. The embedded cultures were mounted for sectioning either
parallel or perpendicular to the culture surface. Initially, blocks were thick sectioned, stained
with toluidine blue, and examined by light microscopy. Areas of interest were thin sectioned
with a diamond knife and stained with saturated uranyl acetate in 50% ethanol followed by
bismuth oxynitrate hydrate (28). The sections were examined on a Zeiss 10A electron mi-
croscope.
Nucleic Acid Hybridization Studies.
￿
Total cellular RNA was isolated from macrophage cul-
tures using a modification ofthe single-step acid guanidinium thiocyanate-phenol-chloroform
procedure (29) (RNAzol; Cinna/Biotecx Laboratories International, Inc., Friendswood, TX).
DNA was also obtained from this extraction and further purified using proteinase K and
DNAse-free RNAse. RNA or DNA were blotted onto nitrocellulose, hybridized with a 32p-
labeled HIV-1 probe, pARV2 (30), a partial proviral clone of HIV1SF2 (the gift ofDr. Paul
Luciw, University of California, Davis, CA), and analyzed by autoradiography.
Results
Time Course ofHIVInfection in UntreatedMacrophages.
￿
In the absence of any treat-
ment, MDM readily supported the replication of the HTLVIIIBa-L/85 macro-
phage-tropic strain of HIV1. Immediately after infection, supernatants routinely
contained <30 pg/ml of p24 core antigen (the threshold of detection in this assay),
indicating the effectiveness ofthe washing procedure used to remove free input virus
(Fig. 1). By day 1, however, a small amount of p24 (100-300 pg/ml) appeared in
all supernatants, and may represent residual virus that was inaccessible to the washing
procedure. Thereafter, p24 antigen in the supernatant markedly increased by day
6 and reached a plateau level in -10 d. The final levels ofp24 antigen achieved varied
between experiments by an order of magnitude, which may reflect differences be-
tween macrophage donors or the day of culture on which the cells were infected
(data not shown).
Ultrastructure ofHIVinfectedMacrophages.
￿
HIV infection of untreated MDM led
to the formation of multinucleated giant cells by day 6 (Fig. 2). When fixed and
embedded on the culture dish and sectioned perpendicular to its surface, a polariza-
tion ofvirion assembly was seen. Virions were most abundant in a region character-
ized by intracytoplasmic vesicles containing numerous interdigitating microvilli,
m a
N a
J
KORNBLUTH ET AL.
￿
1139
FIGURE 1.
￿
Semi-log plot of the time course
ofp24 core antigen accumulation in treated-
vs.-control cultures. MDM were infectedwith
HIV (MOI = 1), washed to remove input
virus, and treated with IFN-a (5,000 U/ml),
IFN-.y (5,000 U/ml), or LPS (10 wg/ml). Ali-
quots of the supernatant medium were har-
vested at the times indicated after infection,
and analyzed for p24 core antigen. The logio
of the mean p24 pg/ml of duplicate cultures
is shown.1140
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reminiscent of the plasmalemma found at the surface of macrophages. These areas
appeared immediately apical to a region of very densely stained cytoplasm and ex-
tensive, dilated smooth endoplasmic reticulum N5 wm above the surface of the cul-
ture dish (Fig. 2). Proceeding apically toward the free surface of the giant cell, the
intracytoplasmic vesicles became larger and the number of virions per vesicle de-
creased. Although virions were occasionally found budding from the plasma mem-
brane, most budding particles were seen in small intracytoplasmic vesicles (Fig. 3,
A-C). Characteristically, vesicles with the highest number of virions had an electron-
dense coating (Figs. 2 and 3).
Cumulatively, more than athousand virionswere seen in sections from untreated,
HIVinfected cultures. In contrast, no multinucleated giant cells or virionswere seen
in cultures treated with 1,000 U/ml of either IFN-a or IFN-y, 100 ng/ml LPS, or
in uninfected cultures (see below). Also, there was no evidence of incomplete virion
assembly or virus accumulation inside the cells treated with interferon or LPS.
EffectsofInterferons, LPS, andCytokinesonHIVInfection inMacrophages.
￿
To evaluate
the effects of INF-a, IFN-y, and LPS, these agents were added to macrophage cul-
tures immediately after HIV infection. A single addition of each of these agents
was capable of reducing p24 antigen accumulation by 1,000-fold (Fig. 1). Antigen
accumulation waspreventedandnot merely delayed, whichindicatesthat the produc-
tion of additional virions was prevented. However, a low-level(<1,200 pg/ml) ofp24
antigen was found in the media of treated cultures in all experiments. While this
is compatible with the persistence of input virus not removed by the washing proce-
dure, the possibility that some virus replication resists these treatments cannot be
excluded.
A dose-response study was performed to quantitate these effects further (Fig. 4).
In four experiments, treatmentwith 100-1,000 U/ml (30-300 pM) ofIFN-aor 10-100
U/ml (25-250 pM)ofIFN-y48 hbefore infection was sufficient to reduce viralproduc-
tion maximally, as measured by the accumulation ofp24 antigen in thesupernatant
14 d later. The slope of the dose-response to LPS was consistently less steep than
that of the interferons, and 100 ng/ml was required to reduce p24 antigen release
10-fold. In contrast, IL-4 was much less effective, and the apparent effects at high
doses could be attributed to endotoxin contamination (data not shown).
In separate experiments(Fig. 5), IFN-O at 10-100 U/ml (3-30pM) also protected
MDM from HIV A single addition of M-CSF (fromCetusCorp.) (Fig. 5) or repeated
FIGURE 2 .
￿
Ultrastructure of HIVinduced multinucleated giant cells. MDM were infected with
HIV at MOI = 1. 6 d later, the cultures were fixed and processed for transmission electron mi-
croscopy. In this figure, a single multinucleated giant cell from an untreated, infected culture
was sectioned perpendicular to the culture dish surface to reveal the differences between basal
(B), medial (M), and apical (A) areas of the cell. Examination of thick sections revealed at least
18 nuclei in this single cell (not shown). The basal portion ofthe cell was characterized by a dense
cytoplasm and dilated smooth endoplasmic reticulum. The prominent intracytoplasmic vesicles
were characterized by extensive interdigitation of microvilli (arrowheads) in the medial area of
the giant cell. Progressing toward the apical (free) surface, the number of virions within these
vesicles decreased and the amount ofluminal space increased. Numerous intracytoplasmic vesicles
with membranes containingelectron-dense deposits (arrows) were also seen. x 3,200; bar = 5 /Am.
(Top) Enlargement ofboxed area below. Numerousvirions are seen within intracytoplasmicvesicles
present in the medial layer of the cell. x48,000.1142
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FIGURE 4
￿
Log-log plot of the dose-
response curves of anti-HIV treat-
ments .MDMwere pretreated for48 h
with the indicated doses ofIFN-y, IFN-
a, LPS, or IL-4, then infected with
HIV (MOI = 1), washed, and the
treatments readded . Supernatants were
collected for p24 core antigen assay 14 d
later, and the loglo of the mean p24
pg/ml of duplicate cultures is shown .
Multinucleated giant cells were absent
in cultures treated with >1,000 U/ml
of IFN-a, >100 U/ml of IFN-y,
10
￿
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￿
100 300 1000 3000 10000
￿
>1,000 ng/ml of LPS, and >1,000
U/ml (LPS ng/ml)
￿
U/ml of IL-4 .
additions ofM-CSF (data not shown) minimally enhanced the replication ofHIV .
(The larger form ofM-CSF from Genetics Institute also didnot affect HIV replica-
tion) . However, because this study used an already highly permissive in vitro infec-
tion system, the replication-enhancing effects of cytokines such as M-CSF (6) may
bemasked by the high background . GM-CSF partially protectedMDM from HIV
in two experiments (one ofwhich is shown in Fig . 5, usingGM-CSF from Genetics
Institute), but had no effect in two other experiments, and actually enhanced HIV
replication in one experiment (data not shown) . IL-1(3, IL-2, IL-6,TNFa, and lym-
photoxin (TNF0) were inactive (Fig. 5 andTable I) . In addition, unstimulatedPBMC
do not constitutively release into their supernatant any factor active in this experimental
system, whereas thelymphokine-rich supernatant ofCon A-stimulated PBMC (which
contained IFN-y ; data not shown) reduced p24 accumulation N30-fold (Table I) .
Since p24 core antigen accumulation might not adequately reflect the release of
infectious virus, supernatants were used to inoculate additional macrophage indi-
cator cultures, which in turn were evaluated for multinucleated giant cellsandproduc-
tion of p24 antigen . Whereas supernatants from untreated cultures contained >103
TCID5o/ml, no infectious virus could be detected in the supernatants of cultures
pretreated with IFN--y (1,000 U/ml), IFN-a(1,000 U/ml), orLPS (1 fog/ml) . To show
that this was not due to carry over of interferon or LPS into the indicator cultures,
neutralizing antibodies or polymyxin B were added respectively, but still no infec-
tious virus could be detected in the treated cultures .
Kinetics ofInterferon and LPS Effects.
￿
To evaluate the stage of infection at which
IFN-a, IFN-y, or LPS acted, MDM were washed four times and treated with high
doses of IFN-y, or IFN-a or LPS initiated at increasing intervals after infection .
Interferons or LPS added as late as 3 d after infection with HIV still decreased the
release ofp24 antigen into the supernatant (Fig. 6) . By day 6 after infection, how-
FIGURE 3 .
￿
Ultrastructure of HIV budding . Montagefrom the same culture as Fig . 2 . Virions
were seen budding into small intracytoplasmic vesicles (A, B, andC ; x95,000 . Bar = 0.1 Am.
Themorphology ofHIV particles ranged from ring-shaped immature forms to those with single
or multiple condensed nucleoids with a characteristic cylinder shape (D-I; x 95,000) . Electron-
dense, membrane-associated deposits (arrows) were frequently seen in intracytoplasmic vesicles
containing numerous virions (J andK ; x 48,000).1144
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TABLE I
Loglo mean
pg/ml
5.04
4.98
5.00
4.59
4.04
4.80
4.85
5 .05
4.76
4.79
4.86
4.55
4.45
4.92
5.11
5.08
4.86
4.85
4.97
4.80
3.32
3.41
3.18
FIGURE 5. Log-log plot of the dose-
response curves of anti-HIV treatments.
MDM were pretreated for 18 h with the
indicated doses of IFN-a, IFN-0, IL-6,
GM-CSF, and M-CSF, then infected with
HIV (MOI = 0.1), washed, and the treat-
ments re-added. Supernatants were col-
lected forp24 core antigen assay 10 d later,
and the loglo of the mean p24 pg/ml of
duplicate cultures is shown. Multinucle-
ated giant cells were absent in cultures
treated with 31,000 U/ml of IFN-a and
310 U/ml of IFN-0, but were not
prevented by IL-6, GM-CSF, and M-CSF
Data for M-CSF from Cetus Corp, are
shown, and are essentially identical to data
for M-CSF from Genetics Institute.
p24 Cytopathology
MDM were pretreated with the above agents for 18 h, infected with HIV (MOI
= 0.1), and washed four times to remove input virus. After replacing the treat-
ment agents, the cultures were incubated for 12 d. p24 core antigen was mea-
sured in the culture supernatants and they are reported as the loglo of the mean
of duplicate cultures. Cytopathology was scored by the presence or absence of
multinucleated giant cells.
Cytokine Dose
IL-10 0
U/ml 1
3
10
30
IL-2 1
U/ml 10
100
1,000
TNF-a 1
U/ml 10
100
1,000
Lymphotoxin 1
(TNF-0) 10
U/ml 100
1,000
PBMC Control 3%
Supernatant 10%
(Percent volume) 30o7o
PBMC-Con A 3%
Supernatant 10%
(Percent volume) 30%KORNBLUTH ET AL . 1145
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ever, these agents were no longer effective in preventing the accumulation of p24
antigen.
Effects ofInterferons andLPSon HIVGene Expression in Macrophages.
￿
Although IFN-
a, IFN-y, and LPS suppressed the release of p24 antigen and infectious virus from
MDM into theirculturemedia, and elminated theformation ofvirions seen by elec-
tron microscopy, thesetechniques didnot completely rule out the expression ofviral
genes inside the cells. Consequently, nucleic acid hybridizationwas used to evaluate
the formation ofRNA transcripts and DNA provirus within these cells. Infected
MDM thatwere not treated with cytokines or LPS contained HIVRNA andDNA
(Fig . 7) . In contrast, IFN-a, IFN-y, or LPS-treatedMDM showed no evidence of
viralRNA transcripts or provirus formation . Thus, in the treated cultures, the ex-
pression ofnonstructural genes and theformation ofproviralDNA arealso prevented.
Discussion
In this report, IFN-a, IFN-0, IFN-y, and LPS were shown to protect cultured
macrophages from productive infection with a macrophage-tropic strain ofHIV1 .
FIGURE 7 .
￿
Effect ofanti-HIV treatments on viral nu-
cleic acids in MDM. MDMcultures (6 x 106 cells per
25-cm2 flask) were infected with HIV (MOI = 0.1),
washed, and then treatedwith IFN-y (1,000 U/ml), IFN-
a (1,000 U/ml), or LPS (1 jug/ml) where indicated, 14 d
after infection, supernatants were collected for p24 assay
and viral titration. CellularRNA andDNA were pro-
cessed as described, slot-blotted onto nitrocellulose, hy-
bridized with a 32RHIV1 probe under stringent condi-
tions, and autoradiographed . (A) Total cellular RNA ;
(B) undigestedDNA . Only untreatedMDM contained
detectable viralRNAor DNA, and supernatant medium
from this culture contained 10535 pg/ml of p24 core anti-
gen and >103TCIDso/ml of infectious HIV In contrast,
IFN-y-, IFN-a-, and LPS-treatedMDM did not con-
tain detectable viral RNA or DNA, and supernatant
medium from these cultures contained <102.6 pg/ml of
p24 core antigen and no detectable infectious HIV .1146
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Since immunological reactions lead to interferon production, anti-HIV immunity
(either natural or induced by a suitable vaccine) may indirectly limit the spread of
HIV infection by protectinguninfected cells, thereby augmenting cytotoxic mecha-
nisms for the removal ofcells that are already infected. Since several other cytokines
do not protect macrophages in this system, the protection afforded by interferons
and LPS must be specifically induced.
Interferons are known to inhibit the production ofinfectious retroviruses by in-
terfering withvirus assembly and release (31). Consistent with theselate effects, we
found that IFN-a, INF--y, or LPS are effective even when added 3 d after exposure
ofcells to HIV at a multiplicity of infection of 1 TCID5o/cell. This observation sug-
gests that these agents act at a point in the viral life cycle beyond the early events
of virus binding, penetration, and uncoating. Interference with reverse transcrip-
tion and the generation ofproviral DNA, the next step in the retroviral replication,
are suggested by the absence of detectable viral DNA in the treated macrophages.
This might occur by inhibition ofviral reverse transcriptase by interferon-induced
2-5A oligonucleotides, as reported for the avian myeloblastosis virus enzyme (32).
However, this conclusion cannot be supported from the data for two reasons: (a)
The method used to detect proviral DNA is not sensitive enough todetect low levels
ofDNA provirus. (b) The definition ofinterferon action is best established during
a single cycle of viral replication (33); for example, in HIVinfected CEM cells (a
Tcellleukemia cell line), virus-producing cells arereinfected bytheirprogenyviruses,
resulting inthe generation ofmultiple copies ofDNA provirus per cell, whichcorre-
lates with the cytopathic effects of HIV in this cell line (34). By analogy, if macro-
phages become reinfected bytheir progeny viruses andifmultiple rounds ofreinfec-
tion arenecessaryto sustain productive infection, theninterferon-induced inhibition
of virus release alone would yield data indistinguishable from an effect on reverse
transcription. Consequently, further studies are required to clarify the mode ofac-
tion ofinterferon and LPS and the fate of HIV upon entry into an interferon- or
LPS-treated macrophage.
Further studies are also required to determine if all HIV isolates capable of in-
fecting macrophages are equally susceptible to interferons or LPS inhibition. It is
possible that HIV adapts to culture conditions as a result of in vitro mutation and
selection pressure. By preparing our viral stock under endotoxin-free conditions,
we may have inadvertently selected for an interferon- and LPS-sensitive strain of
HIV We intend totestthispossibilityusingvirusesisolated by a differenttechnique(6).
LPS and interferons (especially IFN-y) are though to "activate" certain macro-
phage functions, yet these agents protected MDMin these experiments. We found
no evidence that LPS worked indirectly by inducing the secretion ofinterferon . Al-
though LPS is known to stimulate macrophage production of IL-6 (IFN02), IL-6
has no protective effect on its own. Furthermore, no interferon was detectable in
the supernatants from LPS-stimulated MDM using a plaque-reduction assay for
vesicular stomatitis virus on MDBK cells (data not shown). Whatever the mecha-
nism, theseresults indicate that inadvertent endotoxin contamination ofmedia and/or
serum (21) mayconfoundtheresultsofantiviral studies inmacrophages. Endotoxin
contamination may contribute to the differences between our results and those re-
cently reported by Koyanagi etal. (35). These authors studied MDMthat had been
isolated by adherence, exposed to activated complement, detached by EDTA andKORNBLUTH ET AL.
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scraping, and infected in the presence ofthe detergent polybrene. Endotoxin levels
were not monitored ineither the MDMcultures orthe PBMC cultures used togrow
the viral stocks that they used. In contrast, we have used essentially endotoxin-free
conditions and have verified that the MDM were not artifactually activated by the
culture conditions. Theuninfected MDMused in these experiments did not release
IL-1 orTNF detected bybioassays, and did not contain detectable mRNA for IL-1,
TNF, IL-6, or tissue factor, although LPS readily induced the expression ofthese
genes(datanot shown). This patternofgene expression isconsistent with a"resting"
ornonactivated macrophage phenotype. By using MDMofdefined activation pheno-
type, anadditional element ofexperimental control is made available. These factors
may account for the >10-fold lower level ofviral replication in the control cultures
ofKoyanagi et al. (based on p24 antigen levels) as compared with the data reported
here. Suboptimal viral replication may explain the sensitivity oftheir assay system
to viral-enhancing agents, such as colony-stimulating factors. In contrast, our ex-
periments may have used a nearly optimal system for viral replication, accounting
for the sensitivity of our assay system to inhibitory agents .
Macrophages areimportanthost cells for lentiviruses suchas HIV(1-14) and visna-
maedi (36, 37). In sheep, the restricted replication ofvisna-maedi virus in macro-
phages has been associated with the production ofan unusual immune interferon
(36, 37). Interestingly, an unusual type of acid-labile IFN-a has been detected in
the serum of HIVinfected individuals (38). A protective function for this type of
interferon has not yet been demonstrated, and its presence in HIV infection may
actually correlate with a worsened prognosis (39).
Neutralizing antibody to IFN-a has been reported to increase the yield of HIV
in PBMC cultures from HIV-infected individuals (40). Reciprocally, the addition
of IFN-a or INFO, but not IFN-y, has been reported to suppress the replication
of Tlymphotropic strains of HIV in PBMC (41, 42). In cell lines used as models
ofHIV infection, IFN-a and IFN-y are similarly active (43-47). However, in HIV-in-
fected individuals in vivo, IFN-a does not control non-HIV viral infections effec-
tively (48, 49), and the induction ofRNAse L activity by IFN-induced 2-5A is im-
paired inPBMC from AIDSpatientsin vitro(50). Consequently, it cannot beassumed
that macrophages from HIV-infected individuals will be protected from HIV by
interferons as efficiently as macrophages from the uninfected donors used in our
experiments. Nevertheless, it is encouraging that macrophages from AIDS patients
have an appropriate enhancement of H202 release after IFN-y treatment in vivo
and in vitro (51). In this report, we demonstrate the activity of IFN-a, IFN-a, and
IFN-y againstamacrophage-tropicstrain ofHIV-1 usingcultured macrophages from
normal donors. Since the macrophage may be the first cell type to become infected
after exposure to HIV (6, 14), it would be useful to monitorthe effects ofinterferons
on monocyte/macrophage infection in clinical trials with these agents.
Summary
To determine the effects ofimmunomodulatory agents upon HIV replication in
macrophages, cultured monocyte-derived macrophages were treated with various
substances and then infected with a macrophage-tropic strain of HIV1. Pretreat-
ment with HFN-ca, IFN-#, and IFN-y, or bacterial LPS prevented viral replication
in macrophages. In treated cultures, little orno infectious HIV or p24 core antigen1148
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was released into the supernatant, no virions were seen by electron microscopy, no
viral RNA or DNA was detectable in the cell lysates, and no cytopathology (as deter-
mined by multinucleated giant cell formation) occurred. In contrast, pretreatment
with a wide dose range of recombinant IL-10, IL-2, IL-4, IL-6, M-CSF, TNF, or
lymphotoxin failed to protect macrophages from productive infection by HIV. A
consistent effect ofgranulocyte/macrophage-CSF on HIV replication in macrophages
was not observed.
In dose response studies, pretreatment with -100 U/ml of IFN-a, -10 U/ml of
IFN-a, or -100 U/ml of IFN-y was sufficient to prevent virion release maximally
and to prevent cytopathology completely. In kinetic studies, IFN-a, IFN-'r, or LPS
were added to the macrophage cultures either before or after infection with HIV.
Even when added 3 d after infection with a multiplicity of 1 50% tissue-culture in-
fectious dose per cell, all threetreatments markedly reduced virion release, suggesting
that these agents act at a point in the viral life cycle beyond the early events of virus
binding, penetration, and uncoating.
These data indicate that HIV replication in previously uninfected macrophages
may be regulated by an inducible host cell mechanism. These findings may explain
the restricted replication of HIV in macrophages in vivo and suggest an antiviral
role for interferons in the therapy of HIV infection.
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